Quintana, Daniel S. http://orcid.org/0000-0003-2876-0004
Westlye, Lars T. http://orcid.org/0000-0001-8644-956X
Alnæs, Dag http://orcid.org/0000-0001-7361-5418
Kaufmann, Tobias
Mahmoud, Ramy A.
Smerud, Knut T.
Djupesland, Per G.
Andreassen, Ole A.
Article History
Received: 22 March 2018
Revised: 27 September 2018
Accepted: 1 October 2018
First Online: 16 October 2018
<!--Emphasis Type='Bold' removed-->Funding and disclosure:
: This study was supported by the Research Council of Norway and OptiNose AS (Grant no. BIA 219483) and an Excellence Grant for the Novo Nordisk Foundation (NNF16OC0019856). P.G.D. is an employee of OptiNose AS, Oslo, Norway and owns stock and stock options in OptiNose. O.A.A. has received speaker’s honoraria from GSK, Lundbeck, and Otsuka for work not directly relevant to the submitted manuscript. R.A.M. is an employee of OptiNose US, Yardley, PA, USA and owns stock and stock options in OptiNose. K.T.S. is employed by Smerud Medical Research International AS, a CRO receiving fees for clinical trial services from OptiNose AS. The other authors declare no competing interests.